Beom-Jun Kim1, Mark W Hamrick2, Hyun Ju Yoo3, Seung Hun Lee1, Su Jung Kim3, Jung-Min Koh1, Carlos M Isales4. 1. Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea. 2. Department of Cellular Biology and Anatomy, Medical College of Georgia, Augusta University, Augusta, Georgia 30912. 3. Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea. 4. Department of Medicine, Medical College of Georgia, Augusta University, Augusta, Georgia 30912.
Abstract
CONTEXT: Studies in aged mice support a role for kynurenine, a tryptophan metabolite, in age-induced bone loss; however, the role of kynurenine in human bone metabolism is not well understood. OBJECTIVE: To assess whether the kynurenine level in bone marrow (BM) aspirates, directly reflecting the bone microenvironment, is associated with osteoporosis-related phenotypes and bone biochemical markers. DESIGN AND SETTING: A case-control study conducted in a clinical unit. PARTICIPANTS AND MAIN OUTCOME MEASURES: BM samples were collected from 72 patients at the time of hip surgery for either fragility hip fracture (HF) (n = 27) or for other causes (n = 45). In these samples, kynurenine was measured by liquid chromatography-tandem mass spectrometry, and the levels of tartrate-resistant acid phosphatase 5b (TRAP5b), bone-specific alkaline phosphatase (BSALP), receptor activator of nuclear factor-κB ligand (RANKL), and osteoprotegerin (OPG) were measured by immunoassay. RESULTS: Age was positively correlated with BM kynurenine level. After adjustment for confounders, subjects with fragility HF had a 39.7% higher BM kynurenine level than those without, and the OR per SD increment in BM kynurenine level for fragility HF was 3.80. The BM kynurenine level was inversely associated with bone mass at the total femur. Higher kynurenine concentrations were significantly associated with higher TRAP-5b and RANKL levels, but not with BSALP and OPG levels, in BM plasma. CONCLUSION: These results suggest that increased kynurenine levels during aging may contribute to the bone fragility seen in the elderly through increased bone resorption, with a resultant imbalance in bone remodeling.
CONTEXT: Studies in aged mice support a role for kynurenine, a tryptophan metabolite, in age-induced bone loss; however, the role of kynurenine in human bone metabolism is not well understood. OBJECTIVE: To assess whether the kynurenine level in bone marrow (BM) aspirates, directly reflecting the bone microenvironment, is associated with osteoporosis-related phenotypes and bone biochemical markers. DESIGN AND SETTING: A case-control study conducted in a clinical unit. PARTICIPANTS AND MAIN OUTCOME MEASURES: BM samples were collected from 72 patients at the time of hip surgery for either fragility hip fracture (HF) (n = 27) or for other causes (n = 45). In these samples, kynurenine was measured by liquid chromatography-tandem mass spectrometry, and the levels of tartrate-resistant acid phosphatase 5b (TRAP5b), bone-specific alkaline phosphatase (BSALP), receptor activator of nuclear factor-κB ligand (RANKL), and osteoprotegerin (OPG) were measured by immunoassay. RESULTS: Age was positively correlated with BM kynurenine level. After adjustment for confounders, subjects with fragility HF had a 39.7% higher BM kynurenine level than those without, and the OR per SD increment in BM kynurenine level for fragility HF was 3.80. The BM kynurenine level was inversely associated with bone mass at the total femur. Higher kynurenine concentrations were significantly associated with higher TRAP-5b and RANKL levels, but not with BSALP and OPG levels, in BM plasma. CONCLUSION: These results suggest that increased kynurenine levels during aging may contribute to the bone fragility seen in the elderly through increased bone resorption, with a resultant imbalance in bone remodeling.
Authors: Xiangdong Liu; Niu Shin; Holly K Koblish; Gengjie Yang; Qian Wang; Kathy Wang; Lynn Leffet; Michael J Hansbury; Beth Thomas; Mark Rupar; Paul Waeltz; Kevin J Bowman; Padmaja Polam; Richard B Sparks; Eddy W Yue; Yanlong Li; Richard Wynn; Jordan S Fridman; Timothy C Burn; Andrew P Combs; Robert C Newton; Peggy A Scherle Journal: Blood Date: 2010-03-02 Impact factor: 22.113
Authors: Matthew T Drake; Bhuma Srinivasan; Ulrike I Mödder; James M Peterson; Louise K McCready; B Lawrence Riggs; Denise Dwyer; Marina Stolina; Paul Kostenuik; Sundeep Khosla Journal: J Clin Endocrinol Metab Date: 2010-07-14 Impact factor: 5.958
Authors: M Pertovaara; A Raitala; T Lehtimäki; P J Karhunen; S S Oja; M Jylhä; A Hervonen; M Hurme Journal: Mech Ageing Dev Date: 2006-02-28 Impact factor: 5.432
Authors: Dima W Alhamad; Husam Bensreti; Jennifer Dorn; William D Hill; Mark W Hamrick; Meghan E McGee-Lawrence Journal: J Mol Endocrinol Date: 2022-08-22 Impact factor: 4.869
Authors: Jessica L Pierce; Rachel L Roberts; Kanglun Yu; Riley K Kendall; Helen Kaiser; Colleen Davis; Maribeth H Johnson; William D Hill; Carlos M Isales; Wendy B Bollag; Mark W Hamrick; Meghan E McGee-Lawrence Journal: Exp Gerontol Date: 2019-12-17 Impact factor: 4.032
Authors: Ahmed M Elmansi; Khaled A Hussein; Sergio Mas Herrero; Sudharsan Periyasamy-Thandavan; Alexandra Aguilar-Pérez; Galina Kondrikova; Dmitry Kondrikov; Nada H Eisa; Jessica L Pierce; Helen Kaiser; Ke-Hong Ding; Aisha L Walker; Xue Jiang; Wendy B Bollag; Mohammed Elsalanty; Qing Zhong; Xing-Ming Shi; Yun Su; Maribeth Johnson; Monte Hunter; Charles Reitman; Brian F Volkman; Mark W Hamrick; Carlos M Isales; Sadanand Fulzele; Meghan E McGee-Lawrence; William D Hill Journal: Bone Rep Date: 2020-04-23
Authors: Kehong Ding; Meghan E McGee-Lawrence; Helen Kaiser; Anuj K Sharma; Jessica L Pierce; Debra L Irsik; Wendy B Bollag; Jianrui Xu; Qing Zhong; William Hill; Xing-Ming Shi; Sadanand Fulzele; Eileen J Kennedy; Mohammed Elsalanty; Mark W Hamrick; Carlos M Isales Journal: Exp Gerontol Date: 2020-02-20 Impact factor: 4.032